Our modular FHAB construct utilizes a validated, uniquely configured, albumin-binding approach to deliver selected payloads directly to the tumor microenvironment for enhanced penetration, retention and local activation.
Our modular FHAB construct utilizes a validated, uniquely configured, albumin-binding approach to deliver selected payloads directly to the tumor microenvironment for enhanced penetration, retention and local activation.
The Guidant FHAB Mechanism of Action
The Guidant FHAB Mechanism of Action
Our Technology Platform
Our Technology Platform
Guidant BioTherapeutics
Guidant BioTherapeutics
Guidant Bio’s deep knowledge of immune biology is complemented by our extensive drug discovery and product development expertise. Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a fully modular navigated delivery(™) platform.
Human Serum Albumin (HSA) is naturally present in the bloodstream and is the predominant protein in blood plasma. Albumin is actively transported to and accumulates at sites of inflammation, including tumors. Following administration, Guidant's FHAB-conjugated therapies bind to and "hitch-hike" on patients' endogenous albumin for active transport to the target tissues, allowing for longer half-life and safer and more effective therapies.
Guidant Bio’s deep knowledge of immune biology is complemented by our extensive drug discovery and product development expertise. Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a fully modular navigated delivery(™) platform.
Human Serum Albumin (HSA) is naturally present in the bloodstream and is the predominant protein in blood plasma. Albumin is actively transported to and accumulates at sites of inflammation, including tumors. Following administration, Guidant's FHAB-conjugated therapies bind to and "hitch-hike" on patients' endogenous albumin for active transport to the target tissues, allowing for longer half-life and safer and more effective therapies.
Technology founded by Industry Expertise
Technology founded by Industry Expertise
Technology Overview
Technology Overview
A Modular Drug Delivery Platform
A Modular Drug Delivery Platform
FHAB Platform
FHAB Platform
FHAB Platform
FHAB Platform
Versatile discovery platform
Versatile discovery platform
Albumin Binding
Albumin Binding
Immune Activation with Dual-Cytokines
Immune Activation with Dual-Cytokines
Navigated Delivery
Navigated Delivery
Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration. The FHAB single-chain antibody fragment was selected to bind at normal pH, as well as at the acidic pH typically found in the tumor microenvironment (TME).
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor microenvironment, affording it a greater chance to generate an anti-cancer immune response.
Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration. The FHAB single-chain antibody fragment was selected to bind at normal pH, as well as at the acidic pH typically found in the tumor microenvironment (TME).
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor microenvironment, affording it a greater chance to generate an anti-cancer immune response.
Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration. The FHAB single-chain antibody fragment was selected to bind at normal pH, as well as at the acidic pH typically found in the tumor microenvironment (TME).
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor microenvironment, affording it a greater chance to generate an anti-cancer immune response.
Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration. The FHAB single-chain antibody fragment was selected to bind at normal pH, as well as at the acidic pH typically found in the tumor microenvironment (TME).
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor microenvironment, affording it a greater chance to generate an anti-cancer immune response.
Our proprietary albumin-binding single-chain antibody fragment (scFv) binds at a uniquely selected site on the albumin molecule, while allowing albumin’s native binding to the FcRn, gp60, and SPARC.for navigated delivery(™), accumulation and retention in inflamed tissue, including tumors.
We are actively leveraging our proprietary platform to develop two distinct pipelines:
bi-functional cytokines as immune-activating therapeutics
Next generation antibody drug conjugates (ADCs) allowing for dual binders and dual toxins on the same ADC and all the benefits of navigated delivery.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
Our proprietary albumin-binding single-chain antibody fragment (scFv) binds at a uniquely selected site on the albumin molecule, while allowing albumin’s native binding to the FcRn, gp60, and SPARC.for navigated delivery(™), accumulation and retention in inflamed tissue, including tumors.
We are actively leveraging our proprietary platform to develop two distinct pipelines:
bi-functional cytokines as immune-activating therapeutics
Next generation antibody drug conjugates (ADCs) allowing for dual binders and dual toxins on the same ADC and all the benefits of navigated delivery.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
Our customizable platform drives desired immune responses through cytokine payloads with demonstrated anti-tumor potential:
IL-12 (Interleukin-12)
Activates T cells and NK cells.
Reduces immunosuppression by conversion of M2→M1.
Enhances anti-tumor effects by promoting Th1 differentiation and IFN-γ production, crucial for anti-tumor immunity.
IL-18 (Interleukin-18)
Activates T cells and NK cells.
Boosts local IFN-γ production and NK cell activity.
Works synergistically with IL-12 to enhance Th1 responses and overall anti-tumor immunity.
Increases chemokines CXCL9 & 10 expression which increases TH1, NK & CD8+ T cells infiltrate into tumors.
IL-15 (Interleukin-15)
Activates T cells and NK cells.
Enhances local T cell and NK cell activation without promoting Tregs.
Sustains effective anti-tumor immunity in synergy with IL-12, and by decreasing CD8 memory loss by apoptosis, allowing long-term immunosurveillance of the cancer.
Our customizable platform drives desired immune responses through cytokine payloads with demonstrated anti-tumor potential:
IL-12 (Interleukin-12)
Activates T cells and NK cells.
Reduces immunosuppression by conversion of M2→M1.
Enhances anti-tumor effects by promoting Th1 differentiation and IFN-γ production, crucial for anti-tumor immunity.
IL-18 (Interleukin-18)
Activates T cells and NK cells.
Boosts local IFN-γ production and NK cell activity.
Works synergistically with IL-12 to enhance Th1 responses and overall anti-tumor immunity.
Increases chemokines CXCL9 & 10 expression which increases TH1, NK & CD8+ T cells infiltrate into tumors.
IL-15 (Interleukin-15)
Activates T cells and NK cells.
Enhances local T cell and NK cell activation without promoting Tregs.
Sustains effective anti-tumor immunity in synergy with IL-12, and by decreasing CD8 memory loss by apoptosis, allowing long-term immunosurveillance of the cancer.
Publications
Publications
View all publication
View all publication
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
Guidant BioTherapeutics
Guidant BioTherapeutics
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
newsletter
newsletter
The Guidant FHAB Mechanism of Action
Our Technology Platform
Guidant Biotherapeutics
Our modular FHAB construct utilizes a validated, uniquely configured, albumin-binding approach to deliver selected payloads directly to the tumor microenvironment for enhanced penetration, retention and local activation.
Technology founded by Industry Expertise
Technology Overview
Guidant Bio’s deep knowledge of immune biology is complemented by our extensive drug discovery and product development expertise. Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a fully modular navigated delivery(™) platform.
Human Serum Albumin (HSA) is naturally present in the bloodstream and is the predominant protein in blood plasma. Albumin is actively transported to and accumulates at sites of inflammation, including tumors. Following administration, Guidant's FHAB-conjugated therapies bind to and "hitch-hike" on patients' endogenous albumin for active transport to the target tissues, allowing for longer half-life and safer and more effective therapies.
FHAB Platform
FHAB Platform
Versatile discovery platform
Albumin Binding
Navigated Delivery
Immune Activation with Dual-Cytokines
A Modular Drug Delivery Platform
Our proprietary albumin-binding single-chain antibody fragment (scFv) binds at a uniquely selected site on the albumin molecule, while allowing albumin’s native binding to the FcRn, gp60, and SPARC.for navigated delivery(™), accumulation and retention in inflamed tissue, including tumors.
We are actively leveraging our proprietary platform to develop two distinct pipelines:
bi-functional cytokines as immune-activating therapeutics
Next generation antibody drug conjugates (ADCs) allowing for dual binders and dual toxins on the same ADC and all the benefits of navigated delivery.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
The platform is compatible with many biologic drug classes, including interleukins, growth factors, peptides and vaccines.
Our customizable platform drives desired immune responses through cytokine payloads with demonstrated anti-tumor potential:
IL-12 (Interleukin-12)
Activates T cells and NK cells.
Reduces immunosuppression by conversion of M2→M1.
Enhances anti-tumor effects by promoting Th1 differentiation and IFN-γ production, crucial for anti-tumor immunity.
IL-18 (Interleukin-18)
Activates T cells and NK cells.
Boosts local IFN-γ production and NK cell activity.
Works synergistically with IL-12 to enhance Th1 responses and overall anti-tumor immunity.
Increases chemokines CXCL9 & 10 expression which increases TH1, NK & CD8+ T cells infiltrate into tumors.
IL-15 (Interleukin-15)
Activates T cells and NK cells.
Enhances local T cell and NK cell activation without promoting Tregs.
Sustains effective anti-tumor immunity in synergy with IL-12, and by decreasing CD8 memory loss by apoptosis, allowing long-term immunosurveillance of the cancer.
Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration. The FHAB single-chain antibody fragment was selected to bind at normal pH, as well as at the acidic pH typically found in the tumor microenvironment (TME).
By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor microenvironment, affording it a greater chance to generate an anti-cancer immune response.
Publications
View all publication
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |